Core Viewpoint - *ST Suwu has issued a warning regarding the risk of delisting as its stock price has fallen below 1 RMB per share, closing at 0.99 RMB on August 14 [2][10]. Regulatory Compliance - According to the Shanghai Stock Exchange's listing rules, if a company's stock price remains below 1 RMB for 20 consecutive trading days, it may face delisting [4]. - *ST Suwu has previously issued multiple warnings about the potential for forced delisting due to significant legal violations [5][6]. Financial and Operational Issues - The company has been flagged for serious internal control issues, leading to a warning from the China Securities Regulatory Commission (CSRC) regarding potential major legal violations [6]. - *ST Suwu's subsidiaries have been involved in non-commercial trade activities that inflated revenue and profits, resulting in false financial reporting from 2020 to 2023 [6]. - The company's 2024 financial report received an "unable to express an opinion" from the auditing firm, prompting additional delisting risk warnings [6]. Shareholder Information - As of the end of Q1 2025, *ST Suwu had approximately 86,154 shareholders, reflecting a significant increase of 38.76% from the previous quarter [11][12]. Legal Disputes - *ST Suwu's subsidiary, Datuo Medical, has initiated arbitration against RegenBiotech, Inc. for breach of contract, seeking initial compensation of 1.6 billion RMB related to exclusive distribution rights for a product known as "AestheFill" [8][9].